XDclear Technology Enhancements to the GE Vivid Ultrasound Platform – Oct 31, 2013– Fairfield, USA (Techreleased) – GE’s Ultrasound business announced the clearance from the Food and Drug Administration (FDA) for the latest version of its Vivid E9 Cardiovascular Ultrasound system that features XDclear technology.

Vivid E9 with XDclear
Vivid E9 with XDclear

The upgrade provides a boost to the system’s capabilities further enhancing its image quality in 2D, 4D, color and Doppler. The clarity in image could be especially useful in individuals that have proved difficult to scan in the past, such as obese patients.

The World Health Organization (WHO) has defined obesity as a BMI greater than or equal to 30 is obesity. They estimate that overweight and obesity are the fifth leading risk for global deaths. At least 2.8 million adults die each year as a result of being overweight or obese. In addition, 44% of the diabetes burden, 23% of the ischaemic heart disease burden and between 7% and 41% of certain cancer burdens are attributable to overweight and obesity.*

The Centers for Disease Control and Prevention (CDC) stated that the economic consequence of obesity in the United States to be $147 billion in 2008.**

Built from the Vivid E9 platform, the new Vivid E9 with XDclear is designed to help shorten exam time and enhance diagnostic confidence in the adult and pediatric echo labs, during interventions or in the operating room.

The technology’s efficiencies means that patients are minimally exposed to the high-stress setting of the echo lab, interventional suite or the OR. This means conducting an ultrasound examination on a patient who is difficult to scan can result in a quicker scan time, helping lead to reduced anxiety for the patient.

The technology also recently received CE Mark and is available in Europe and the video above features GE engineers discussing the need for the new XDclear technology and the positive impact it can have on healthcare providers.